Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Return on Capital Employed (2025)

Neuphoria Therapeutics (NEUP) has disclosed Return on Capital Employed for 1 consecutive years, with 0.12% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed changed N/A to 0.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.12%, a N/A change, with the full-year FY2023 number at 0.61%, changed N/A from a year prior.
  • Return on Capital Employed was 0.12% for Q4 2025 at Neuphoria Therapeutics, up from 0.14% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.04% in Q2 2025 to a low of 0.14% in Q3 2025.